Sanofi breaks ground on Frankfurt insulin API facility
Sanofi broke ground on a new insulin manufacturing facility at its Frankfurt BioCampus on October 19, advancing a project first announced in August 2024.
The facility will have a 36,000 m² footprint, with full insulin active pharmaceutical ingredient (API) production targeted for 2032, subject to licensing. The groundbreaking marks the start of construction rather than an immediate expansion of manufacturing supply.
The European Commission approved public support for the project in September 2026, according to Sanofi.
Frankfurt is already a major insulin manufacturing site, with activities spanning API production, filling, device assembly and packaging. The new facility forms part of Sanofi's own production network.
Sanofi has not disclosed quantitative API capacity for the project or how the investment will affect production at its existing facilities.